Pszczew (PL)
{name}
{subtitle}
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~65 mi. (Poznań, Poland, +144 more cities)
facility
Szpital Kliniczny Przemienienia Panskiego UM im. K. Marcinkowskiego ( Site 2406)
condition
Clear Cell Renal Cell Carcinoma
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
city
~65 mi. (Poznań, Poland, +176 more cities)
facility
Wielkopolskie Centrum Onkologii im.M.Sklodowskiej-Curie ( Site 2484)
condition
Endometrial Carcinoma, +1 more condition
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
city
~65 mi. (Poznań, Poland, +130 more cities)
facility
Clinical Research Center Sp. z o.o. ( Site 0674)
condition
Bladder Urothelial Carcinoma
drug
BCG solution, +1 more drug
drug type
immunotherapy
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)
city
~65 mi. (Poznań, Poland, +131 more cities)
facility
Szpital Kliniczny im. Heliodora Swiecickiego Uniwers Medyczn ( Site 1703)
biomarker
HER2 Negative
condition
Adenocarcinoma of the Gastroesophageal Junction, +2 more conditions
drug
CAPOX regimen, +3 more drugs
drug type
chemotherapy, +2 more types
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
city
~65 mi. (Poznań, Poland, +93 more cities)
facility
Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego ( Site 2401)
condition
Clear Cell Renal Cell Carcinoma
drug
belzutifan, +1 more drug
drug type
targeted therapy
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)
city
~65 mi. (Poznań, Poland, +127 more cities)
facility
Szpital Kliniczny im. Heliodora Swiecickiego Uniwers Medyczn ( Site 2509)
condition
Hypopharyngeal Squamous Cell Carcinoma, +3 more conditions
drug
lenvatinib, +1 more drug
drug type
immunotherapy, +1 more type
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
city
~65 mi. (Poznań, Poland, +189 more cities)
facility
Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Mar /ID# 241031
biomarker
del(11)(q10), +27 more biomarkers
condition
Myelofibrosis Transformation in Essential Thrombocythemia, +2 more conditions
drug
navitoclax, +1 more drug
drug type
targeted therapy
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)
city
~65 mi. (Poznań, Poland, +62 more cities)
facility
MED-POLONIA Sp.z o.o.
biomarker
ER Negative, +2 more biomarkers
condition
Breast Carcinoma
drug
carboplatin, +2 more drugs
drug type
chemotherapy, +1 more type